MEDIPOST, Inc.

MEDIPOST, Inc. is a leading commercial-stage biotechnology company specializing in the development of umbilical cord-derived stem cell therapies to treat inflammation-driven degenerative diseases. The company's flagship product, CARTISTEM®, is the world's first allogeneic stem cell therapy, used to treat knee cartilage lesions caused by inflammation, approved in Korea in 2012 and used to treat over 30,000 patients. In the United States, CARTISTEM is entering late-stage development as a potential treatment for cartilage defects associated with knee osteoarthritis. In partnership with the Centre for Commercialization of Regenerative Medicine (CCRM), MEDIPOST has established OmniaBio, a cell and gene therapy contract development and manufacturing organization (CDMO) based in Hamilton, Ontario, to manufacture CARTISTEM.